Kura Oncology, Inc. Stock price

Equities

KURA

US50127T1097

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-18 pm EDT 5-day change 1st Jan Change
21.04 USD -5.82% Intraday chart for Kura Oncology, Inc. -7.80% +46.31%
Sales 2024 * - Sales 2025 * 13.19M Capitalization 1.6B
Net income 2024 * -194M Net income 2025 * -216M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 121 x
P/E ratio 2024 *
-9.07 x
P/E ratio 2025 *
-8.73 x
Employees 142
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.37%
More Fundamentals * Assessed data
Dynamic Chart
1 day-5.82%
1 week-10.58%
Current month-0.19%
1 month+2.04%
3 months+71.06%
6 months+112.74%
Current year+46.31%
More quotes
1 week
20.90
Extreme 20.9
23.03
1 month
19.26
Extreme 19.26
24.17
Current year
13.29
Extreme 13.29
24.17
1 year
7.41
Extreme 7.41
24.17
3 years
7.41
Extreme 7.41
30.37
5 years
6.35
Extreme 6.35
43.00
10 years
2.50
Extreme 2.5
43.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 14-08-21
Chief Tech/Sci/R&D Officer 52 20-08-24
Chief Operating Officer 77 19-08-08
Members of the board TitleAgeSince
Director/Board Member 60 21-06-02
Director/Board Member 65 15-04-26
Director/Board Member 55 15-10-13
More insiders
Date Price Change Volume
24-03-18 21.04 -5.82% 1,014,156
24-03-15 22.34 +1.64% 3,345,487
24-03-14 21.98 -3.72% 1,170,025
24-03-13 22.83 +2.33% 685,927
24-03-12 22.31 -2.23% 1,144,747

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of medicines for the treatment of cancer. The Company's pipeline consists of small molecule product candidates that target cancer signaling pathways. The Company's products candidate includes Ziftomenib, Tipifarnib, and KO-2806. The Ziftomenib is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene for the treatment of genetically defined acute myeloid leukemia (AML) patients. Tipifarnib is a potent, selective and orally bioavailable inhibitor of farnesyl transferase. KO-2806, is a next generation farnesyl transferase inhibitor (FTI), which it demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
21.04 USD
Average target price
30.25 USD
Spread / Average Target
+43.77%
Consensus
  1. Stock
  2. Equities
  3. Stock Kura Oncology, Inc. - Nasdaq